Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

mutiple myeloma

- PMLiVE

Keytruda cleared for frontline lung cancer in England – but only after another pricing deal

Keytruda first drug to exit Cancer Drugs Fund and go through Budget Impact Test

- PMLiVE

NICE backs Tesaro’s Zejula via the CDF

Recommends the drug for second-line use in ovarian cancer patients

- PMLiVE

J&J moves quickly ahead with trials of myeloma CAR-T

Expects to start trials during the second half of this year

Janssen & Research Partnership win prestigious BHBIA Best Business Impact award

We are delighted to announce that Janssen and Research Partnership have won the BOBI (Best of Business Intelligence) Award in the Best Business Impact category at the BHBIA annual conference in London for our collaborative market research...

Research Partnership

Bayer symbol

Loxo, Bayer get quick FDA review for ‘precision’ cancer drug

Bayer and Loxo hopeful about novel biomarker-led cancer treatment

- PMLiVE

Daily Brief: Azar blasts pharma, NICE forces MS drug prices down, Xenicos gets $30m funding

News from the frontline of healthcare, pharma and biotech

- PMLiVE

Keytruda gains NICE clearance in first line bladder cancer

MSD extends advantage in immunotherapy with Cancer Drugs Fund clearance

- PMLiVE

Shaping healthcare

Bayer’s Lars Bruening talks about moving to the UK as the market works its way through a series of seismic changes

Sanofi reception

NICE rejects Sanofi’s Dupixent for atopic dermatitis at first call

Dupixent is still too expensive despite discount, says the UK’s cost effectiveness body

Bayer looks to leverage AI across the pharma value chain

Dieter Weinand outlines his hopes for applying artificial intelligence

- PMLiVE

EMA starts review of Xtandi in non-metastatic prostate cancer

The evaluation is based on positive results from the PROSPER trial

- PMLiVE

NICE says OK to Keytruda for bladder cancer via the CDF

Becomes the first immunotherapy recommended for UC after chemotherapy

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links